RETHINK Drug Discovery. This public event will address the latest advances in the field of artificial intelligence and drug discovery.
RETHINK Drug Discovery
Recent advances in chemical synthesis, biological testing, and artificial intelligence (AI) allow for greater automation in the drug discovery process. AI systems that generate novel design suppositions, as well as, cope with multiple design objectives provide a basis for further automation in some aspects of drug discovery. Automation could potentially accelerate time frames for compound design and optimization. It could also enable better decision making in early-stage pharmaceutical discovery that translates into late-stage clinical validation. However, such approaches also raise considerable conceptual, technical, and organizational challenges.
This symposium aims to address the latest advances of this rapidly progressing field of science, by bringing together leading researchers to present the state-of-the-art in drug discovery. Together they will make daring predictions surrounding the possibilities and limitations of drug discovery using machine intelligence.
Free entry. Please register here https://www.eventbrite.com/e/eth-meets-boston-2019-tickets-69986109337
Download (PDF, 595 KB) https://ethz.ch/content/dam/ethz/main/eth-zurich/global/events/2019/ETH%20Meets%20Boston%202019/ProgrammeFlyer_Boston2019_web.pdf
Executive, entrepreneur, advisor
Senior Investigator, Novartis Institutes for BioMedical Research (NIBR)
Professor for Computer-Assisted Drug Design, ETH Zurich
Connor W. Coley
Postdoc, Broad Institute, MIT
Chief Scientific Officer, ORIG3N
Friday, October 18, 2019
Door opening time: 6.00 pm
75 Northern Avenue, Boston, MA